Shuttle Pharmaceuticals (NASDAQ:SHPH – Get Free Report) and Daiichi Sankyo (OTCMKTS:DSNKY – Get Free Report) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, institutional ownership, profitability, earnings and risk.
Valuation & Earnings
This table compares Shuttle Pharmaceuticals and Daiichi Sankyo”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Shuttle Pharmaceuticals | N/A | N/A | -$11.72 million | ($47.70) | -0.07 |
| Daiichi Sankyo | $14.10 billion | 2.30 | $1.72 billion | $0.94 | 18.49 |
Volatility and Risk
Shuttle Pharmaceuticals has a beta of 0.29, suggesting that its share price is 71% less volatile than the S&P 500. Comparatively, Daiichi Sankyo has a beta of -0.17, suggesting that its share price is 117% less volatile than the S&P 500.
Profitability
This table compares Shuttle Pharmaceuticals and Daiichi Sankyo’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Shuttle Pharmaceuticals | N/A | -408.34% | -138.15% |
| Daiichi Sankyo | 12.32% | 15.75% | 6.91% |
Institutional and Insider Ownership
4.6% of Shuttle Pharmaceuticals shares are owned by institutional investors. 12.6% of Shuttle Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Analyst Recommendations
This is a breakdown of recent ratings and price targets for Shuttle Pharmaceuticals and Daiichi Sankyo, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Shuttle Pharmaceuticals | 1 | 0 | 0 | 0 | 1.00 |
| Daiichi Sankyo | 0 | 1 | 0 | 0 | 2.00 |
Summary
Daiichi Sankyo beats Shuttle Pharmaceuticals on 8 of the 11 factors compared between the two stocks.
About Shuttle Pharmaceuticals
Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers . The company is based in Gaithersburg, Maryland.
About Daiichi Sankyo
Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia. It also provides olmesartan medoxomil antihypertensive agents; NILEMDO, an oral treatment to help in lowering cholesterol; and Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe for reducing cholesterol. In addition, the company offers Canalia for the treatment of type 2 diabetes mellitus; Emgalty for the treatment of migraine attacks; Pralia for the treatment of anti-osteoporosis/inhibitor of the progression of bone erosion associated with rheumatoid arthritis; Ranmark for the treatment of bone complications caused by bone metastasis from tumors; Tarlige for treating pain; Tenelia for the treatment of Type 2 diabetes mellitus; Venofer for the treatment of iron deficiency anemia; and Vimpat, an anti-epileptic agent. Further, it provides vaccines for influenza, measles/rubella infection, and mumps. The company has a development and commercialization agreement with Merck to jointly develop and commercialize Daiichi Sankyo's DXd antibody drug conjugate (ADC) candidates The company was founded in 1899 and is headquartered in Tokyo, Japan.
Receive News & Ratings for Shuttle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shuttle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
